Stay updated on TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.

Latest updates to the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4, indicating a minor deployment or patch; no changes to study data, content, or user-facing functionality are evident in the provided context, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoChange DetectedA new line noting the last known status and associated personnel was added to the study record. This change does not affect trial details or user actions.SummaryDifference0.4%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedFooter now shows Revision: v3.3.3; the previous Revision: v3.3.2 and the HHS Vulnerability Disclosure link have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedMinor textual clarifications: publications are automatically filled from PubMed and may not be about the study; revision updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedThe government funding/operating status notice was removed from the page. The core study details, eligibility criteria, and study status remain unaffected.SummaryDifference0.4%

- Check74 days agoChange DetectedNo significant additions or deletions were detected; the study details and core information remain unchanged, with any observed differences likely cosmetic or layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.